Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iron
Drug ID BADD_D01197
Description A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia.
Indications and Usage Used in preventing and treating iron-deficiency anemia.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB01592
KEGG ID Not Available
MeSH ID D007501
PubChem ID 23925
TTD Drug ID D0Y3TM
NDC Product Code 0220-2054; 62106-5042; 68428-383; 64117-791; 0220-2051; 0164-1152
UNII E1UOL152H7
Synonyms Iron | Iron-56 | Iron 56
Chemical Information
Molecular Formula Fe
CAS Registry Number 7439-89-6
SMILES [Fe]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Foaming at mouth08.01.03.070; 07.05.05.019; 17.02.05.056--Not Available
Skin plaque23.03.03.044--Not Available
Lip pruritus07.05.05.021--Not Available
Poor feeding infant18.04.06.006; 14.03.02.022--Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.035--Not Available
Administration site bruise08.02.04.016; 24.07.06.025; 23.03.11.023; 12.07.04.016--Not Available
Administration site induration12.07.04.022; 08.02.04.022--Not Available
Administration site pain12.07.04.029; 08.02.04.029--Not Available
Agonal respiration02.11.05.001; 22.02.01.033--Not Available
Fear of injection19.06.03.016--Not Available
Fishbane reaction15.03.04.020; 08.06.01.039--Not Available
Gait inability17.02.05.069; 08.01.02.0110.000453%Not Available
Heavy menstrual bleeding21.01.03.0050.001904%Not Available
Infusion related hypersensitivity reaction12.02.05.055; 10.01.03.058--Not Available
Infusion site discolouration23.03.03.084; 12.07.05.026; 08.02.05.026--Not Available
Injection site nerve damage08.02.03.066; 12.07.03.066--Not Available
Intermenstrual bleeding21.01.01.0150.002312%Not Available
Loss of therapeutic response08.06.01.041--Not Available
Periorbital swelling10.01.05.025; 06.08.03.032; 23.04.01.025--Not Available
Sensitive skin23.03.03.097--Not Available
Similar reaction on previous exposure to drug08.06.01.046--Not Available
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.018--Not Available
Therapeutic product effect delayed08.06.01.051--Not Available
Therapeutic product effect incomplete08.06.01.0520.000453%Not Available
Therapy non-responder08.06.01.0630.000680%Not Available
Brain fog19.21.02.017; 16.32.03.050; 17.02.05.077--Not Available
The 14th Page    First    Pre   14    Total 14 Pages